Literature DB >> 15800376

Activity-dependent neurotrophic factor-9 and NAP promote neurite outgrowth in rat hippocampal and cortical cultures.

Virginia L Smith-Swintosky1, Illana Gozes, Douglas E Brenneman, Michael R D'Andrea, Carlos R Plata-Salaman.   

Abstract

Activity-dependent neurotrophic factor (ADNF) is a novel, femtomolar-acting, glial-derived polypeptide (14 kDa) known to protect neurons from a variety of toxic insults. The active site for ADNF function is localized to a 9-amino-acid stretch (SALLRSIPA; ADNF-9). A few years later, a novel ADNF-9-like active peptide (NAPVSIPQ or NAP) was identified and shown to be expressed in the CNS and exhibit an activity profile similar to ADNF-9. Such studies suggest that ADNF-9 and NAP might function like other known neurotrophins and play a role in neural development and maintenance. The purpose of the present studies was to determine if ADNF-9 or NAP affects neurite outgrowth and synaptogenesis in rat hippocampal and cortical cultures. Using MAP2-FITC immunofluorescent labeling, we found that ADNF-9 and NAP promoted neurite outgrowth in a concentration-dependent manner, with maximal activity observed at femtomolar concentrations. Both peptides stimulated robust outgrowth in hippocampal cells (approximately 150% of control; p < 0.01) with a modest effect on cortical cells (approximately 20% of control; p < 0.05) similar to other known growth factors. However, the outgrowth-promoting effect was abolished in the absence of serum, suggesting that soluble factors might be necessary for the neurotrophic activity. Finally, we found that ADNF-9 and NAP increased synaptophysin expression in both rat hippocampal and cortical cultures. These results suggest that ADNF-9 and NAP might contribute to neuronal plasticity associated with development and repair after injury.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15800376     DOI: 10.1385/JMN:25:3:225

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   3.444


  47 in total

1.  Differential patterns of nerve growth factor, brain-derived neurotrophic factor and neurotrophin-3 mRNA and protein levels in developing regions of rat brain.

Authors:  K P Das; S L Chao; L D White; W T Haines; G J Harry; H A Tilson; S Barone
Journal:  Neuroscience       Date:  2001       Impact factor: 3.590

2.  An antagonist to vasoactive intestinal peptide affects cellular functions in the central nervous system.

Authors:  I Gozes; S K McCune; L Jacobson; D Warren; T W Moody; M Fridkin; D E Brenneman
Journal:  J Pharmacol Exp Ther       Date:  1991-06       Impact factor: 4.030

3.  Vasoactive intestinal peptide regulates mitosis, differentiation and survival of cultured sympathetic neuroblasts.

Authors:  D W Pincus; E M DiCicco-Bloom; I B Black
Journal:  Nature       Date:  1990-02-08       Impact factor: 49.962

4.  Neurotrophic factors [activity-dependent neurotrophic factor (ADNF) and basic fibroblast growth factor (bFGF)] interrupt excitotoxic neurodegenerative cascades promoted by a PS1 mutation.

Authors:  Q Guo; L Sebastian; B L Sopher; M W Miller; G W Glazner; C B Ware; G M Martin; M P Mattson
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-30       Impact factor: 11.205

5.  Neurotrophins induce formation of functional excitatory and inhibitory synapses between cultured hippocampal neurons.

Authors:  C Vicario-Abejón; C Collin; R D McKay; M Segal
Journal:  J Neurosci       Date:  1998-09-15       Impact factor: 6.167

6.  Vasoactive intestinal peptide (VIP) prevents neurotoxicity in neuronal cultures: relevance to neuroprotection in Parkinson's disease.

Authors:  D Offen; Y Sherki; E Melamed; M Fridkin; D E Brenneman; I Gozes
Journal:  Brain Res       Date:  2000-01-31       Impact factor: 3.252

Review 7.  A novel signaling molecule for neuropeptide action: activity-dependent neuroprotective protein.

Authors:  I Gozes; M Bassan; R Zamostiano; A Pinhasov; A Davidson; E Giladi; O Perl; G W Glazner; D E Brenneman
Journal:  Ann N Y Acad Sci       Date:  1999       Impact factor: 5.691

8.  Cloning and characterization of the human activity-dependent neuroprotective protein.

Authors:  R Zamostiano; A Pinhasov; E Gelber; R A Steingart; E Seroussi; E Giladi; M Bassan; Y Wollman; H J Eyre; J C Mulley; D E Brenneman; I Gozes
Journal:  J Biol Chem       Date:  2001-01-05       Impact factor: 5.157

9.  NAP, a femtomolar-acting peptide, protects the brain against ischemic injury by reducing apoptotic death.

Authors:  Ronen R Leker; Angella Teichner; Nikolas Grigoriadis; Haim Ovadia; Douglas E Brenneman; Mati Fridkin; Eli Giladi; Jacob Romano; Illana Gozes
Journal:  Stroke       Date:  2002-04       Impact factor: 7.914

10.  NAP mechanisms of neuroprotection.

Authors:  Illana Gozes; Ruth A Steingart; Avron D Spier
Journal:  J Mol Neurosci       Date:  2004       Impact factor: 3.444

View more
  25 in total

1.  A pilot trial of the microtubule-interacting peptide (NAP) in mice overexpressing alpha-synuclein shows improvement in motor function and reduction of alpha-synuclein inclusions.

Authors:  Sheila M Fleming; Caitlin K Mulligan; Franziska Richter; Farzad Mortazavi; Vincent Lemesre; Carmen Frias; Chunni Zhu; Alistair Stewart; Illana Gozes; Bruce Morimoto; Marie-Françoise Chesselet
Journal:  Mol Cell Neurosci       Date:  2010-12-27       Impact factor: 4.314

Review 2.  Microtubule-Tau Interaction as a Therapeutic Target for Alzheimer's Disease.

Authors:  Yanina Ivashko Pachima; Liu-yao Zhou; Peng Lei; Illana Gozes
Journal:  J Mol Neurosci       Date:  2016-02       Impact factor: 3.444

3.  Vasoactive Intestinal Peptide Decreases β-Amyloid Accumulation and Prevents Brain Atrophy in the 5xFAD Mouse Model of Alzheimer's Disease.

Authors:  Orhan Tansel Korkmaz; Hakan Ay; Nurgul Aytan; Isabel Carreras; Neil W Kowall; Alpaslan Dedeoglu; Nese Tuncel
Journal:  J Mol Neurosci       Date:  2018-11-29       Impact factor: 3.444

Review 4.  Signaling pathways in schizophrenia: emerging targets and therapeutic strategies.

Authors:  Caline S Karam; Jacob S Ballon; Nancy M Bivens; Zachary Freyberg; Ragy R Girgis; José E Lizardi-Ortiz; Sander Markx; Jeffrey A Lieberman; Jonathan A Javitch
Journal:  Trends Pharmacol Sci       Date:  2010-06-25       Impact factor: 14.819

Review 5.  Peptide Pharmacological Approaches to Treating Traumatic Brain Injury: a Case for Arginine-Rich Peptides.

Authors:  Li Shan Chiu; Ryan S Anderton; Neville W Knuckey; Bruno P Meloni
Journal:  Mol Neurobiol       Date:  2016-11-14       Impact factor: 5.590

6.  NCAM signaling mediates the effects of GDNF on chronic morphine-induced neuroadaptations.

Authors:  Li Li; Junping Cao; Suming Zhang; Cunjin Wang; Jinfeng Wang; Ge Song; Hongjun Wang; Licai Zhang
Journal:  J Mol Neurosci       Date:  2014-01-08       Impact factor: 3.444

7.  Effects of davunetide on N-acetylaspartate and choline in dorsolateral prefrontal cortex in patients with schizophrenia.

Authors:  L Fredrik Jarskog; Zhengchao Dong; Alayar Kangarlu; Tiziano Colibazzi; Ragy R Girgis; Lawrence S Kegeles; Deanna M Barch; Robert W Buchanan; John G Csernansky; Donald C Goff; Michael P Harms; Daniel C Javitt; Richard Se Keefe; Joseph P McEvoy; Robert P McMahon; Stephen R Marder; Bradley S Peterson; Jeffrey A Lieberman
Journal:  Neuropsychopharmacology       Date:  2013-01-16       Impact factor: 7.853

8.  ADNP differential nucleus/cytoplasm localization in neurons suggests multiple roles in neuronal differentiation and maintenance.

Authors:  Shmuel Mandel; Irit Spivak-Pohis; Illana Gozes
Journal:  J Mol Neurosci       Date:  2008-02-20       Impact factor: 3.444

9.  Ethanol inhibits neuronal differentiation by disrupting activity-dependent neuroprotective protein signaling.

Authors:  Suzhen Chen; Michael E Charness
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-01       Impact factor: 11.205

10.  The NAP motif of activity-dependent neuroprotective protein (ADNP) regulates dendritic spines through microtubule end binding proteins.

Authors:  S Oz; O Kapitansky; Y Ivashco-Pachima; A Malishkevich; E Giladi; N Skalka; R Rosin-Arbesfeld; L Mittelman; O Segev; J A Hirsch; I Gozes
Journal:  Mol Psychiatry       Date:  2014-09-02       Impact factor: 15.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.